<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072641</url>
  </required_header>
  <id_info>
    <org_study_id>ALFGBG-542821</org_study_id>
    <nct_id>NCT03072641</nct_id>
  </id_info>
  <brief_title>Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer</brief_title>
  <official_title>Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DuPont Nutrition and Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if probiotic bacteria have a beneficial effect on
      the colon cancer-associated microbiota and epigenetic alterations in colon cancer. Dietary
      supplementation consists of two ProBion Clinica tablets, yielding a daily dose of 1.4 x 10 ˄
      10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC
      700396), and 0.63 g inulin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in microbiota composition after probiotics use</measure>
    <time_frame>8-78 days depending on time elapsed from inclusion to surgical removal of tumor</time_frame>
    <description>The microbiota composition is analysed at baseline and after probiotics use in tissue and faeces samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epigenetic changes after probiotics use</measure>
    <time_frame>8-78 days depending on time elapsed from inclusion to surgical removal of tumor</time_frame>
    <description>DNA methylation levels are analysed at baseline and after probiotics use in tissue samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>ProBion Clinica</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ProBion Clinica</intervention_name>
    <arm_group_label>ProBion Clinica</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one malignant tumor in the colon

        Exclusion Criteria:

          -  Study subjects with adenomas, or

          -  who received recent antibiotic therapy or

          -  consumed probiotics regularly were excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne A Wettergren, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of surgery, Sahlgrenska Univ. Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vastra Gotaland Region</investigator_affiliation>
    <investigator_full_name>Yvonne Wettergren</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Epigenetics</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

